581 related articles for article (PubMed ID: 23324275)
21. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
[TBL] [Abstract][Full Text] [Related]
22. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
[TBL] [Abstract][Full Text] [Related]
24. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
[TBL] [Abstract][Full Text] [Related]
25. [Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].
Li MH; Xie Y; Wu YZ; Xu DZ; Lu ZM; Hou JL; Jia JD; Wang YM; Zhang SL; Ren H; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2007 Jul; 15(7):481-4. PubMed ID: 17669233
[TBL] [Abstract][Full Text] [Related]
26. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
[TBL] [Abstract][Full Text] [Related]
27. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
[TBL] [Abstract][Full Text] [Related]
28. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.
Zheng Q; Zhu YY; Chen J; Liu YR; You J; Dong J; Zeng DW; Gao LY; Chen LH; Jiang JJ
J Viral Hepat; 2014 Dec; 21(12):909-16. PubMed ID: 24888640
[TBL] [Abstract][Full Text] [Related]
29. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
[TBL] [Abstract][Full Text] [Related]
30. HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.
Ma H; Yang RF; Li XH; Jin Q; Wei L
Chin Med J (Engl); 2016 Sep; 129(18):2212-9. PubMed ID: 27625094
[TBL] [Abstract][Full Text] [Related]
31. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
32. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
33. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
34. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
[TBL] [Abstract][Full Text] [Related]
35. [HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].
Lee CK; Han KH; Suh JH; Cho YS; Won SY; Chon CY; Moon YM; Park IS
Korean J Hepatol; 2005 Mar; 11(1):34-42. PubMed ID: 15788883
[TBL] [Abstract][Full Text] [Related]
36. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
[TBL] [Abstract][Full Text] [Related]
37. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
39. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Buster EH; Flink HJ; Simsek H; Heathcote EJ; Sharmila S; Kitis GE; Gerken G; Buti M; de Vries RA; Verhey E; Hansen BE; Janssen HL
Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
[TBL] [Abstract][Full Text] [Related]
40. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]